Skip to main content

Advertisement

SpringerLink
Log in

Thought disorders among non-demented outpatients with Parkinson’s disease: prevalence and associated factors

  • Movement Disorders - Original Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

The objectives of the study are to evaluate the prevalence and the associated factors of thought disorders in a large cross-sectional population of non-demented out patients with Parkinson’s disease (PD). Four-hundred and nineteen consecutive non-demented PD patients were studied through the DoPaMiP cross-sectional study. Demographic and clinical variables were recorded, including motor and cognitive status, dependency, depressive and anxious symptoms, dysautonomia and sleep disorders. The presence of thought disorders over the past 15 days was assessed by the Unified Parkinson’s Disease Rating Scale part I. Patients with and without thought disorders were compared using parametric tests. Logistic regression was applied to significant data. Thought disorders were present in 105 patients (25%) including vivid dreams in 83 (19.8%), benign hallucinations in 17 (4.1%), and hallucinations without insight in 5 (1.2%). No patient had delusion. Patients with thought disorders were more dependent than the others. Thought disorders were associated with longer PD duration, greater UPDRS scores and the presence of motor complications. Conversely, UPDRS tremor sub-score was lower in patients without thought disorders. Thought disorders were also associated with dysautonomia, lower MMSE score, depression and sleep disorders. Logistic regression identified PD duration, lower MMSE score, depressive and dysautonomic signs as independent risk factors. In conclusion, mild thought disorders were present in 25% of non-demented outpatients with PD, but hallucinations were present in 5% only. Thought disorders were associated with PD duration, depressive and dysautonomic symptoms and lower MMSE score.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aarsland D, Larsen JP, Cummins JL et al (1999) Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 56:595–601

    Article  CAS  PubMed  Google Scholar 

  • Adler CH, Sethi KD, Hauser RA et al (1997) Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 49:393–399

    CAS  PubMed  Google Scholar 

  • Arnulf I, Bonnet AM, Damier P et al (2000) Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology 55:281–288

    CAS  PubMed  Google Scholar 

  • Barnes J, David AS (2001) Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 70:727–733

    Article  CAS  PubMed  Google Scholar 

  • Buysse DJ, Reynolds CF 3rd, Monk TH et al (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213

    Article  CAS  PubMed  Google Scholar 

  • Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep measures in Parkinson’s disease patients with treatment-induced hallucinations. Ann Neurol 34:710–714

    Article  CAS  PubMed  Google Scholar 

  • Fenelon G, Mahieux F, Huon R et al (2000) Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain 123:733–745

    Article  PubMed  Google Scholar 

  • Fernandez HH, Aarsland D, Fenelon G, Friedman JH, Marsh L, Troster AI et al (2008) Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord 23:484–500

    Article  PubMed  Google Scholar 

  • Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43:2227–2229

    CAS  PubMed  Google Scholar 

  • Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45:669–671

    CAS  PubMed  Google Scholar 

  • Goetz CG, Wuu J, Curgian LM, Leurgans S (2005) Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 64:81–86

    PubMed  Google Scholar 

  • Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatr 70:734–738

    Article  CAS  PubMed  Google Scholar 

  • Hosmer DW, Lemshow S (1989) Applied logistic regression. Wiley, Toronto

    Google Scholar 

  • International Association for the Study of Pain, Subcommittee on Taxonomy (1986) Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain Suppl 3:S1–S226

    Google Scholar 

  • Jenkinson C, Fitzpatrick R, Peto V et al (1997) The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357

    Article  CAS  PubMed  Google Scholar 

  • Kempster PA, Williams DR, Selikhova M et al (2007) Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain 130:2123–2128

    Article  CAS  PubMed  Google Scholar 

  • Marinus J, Leentjens AF, Visser M et al (2002) Evaluation of the hospital anxiety and depression scale in patients with Parkinson’s disease. Clin Neuropharmacol 25:318–324

    Article  PubMed  Google Scholar 

  • Negre-Pages L, Regragui W, Bouhassira D et al (2008) Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 23:1361–1369

    Article  PubMed  Google Scholar 

  • Nomura T, Inoue Y, Mitani H et al (2003) Visual hallucinations as REM sleep behavior disorders in patients with Parkinson’s disease. Mov Disord 18:812–817

    Article  PubMed  Google Scholar 

  • Oka H, Yoshioka M, Onouchi K et al (2007) Impaired cardiovascular autonomic function in Parkinson’s disease with visual hallucinations. Mov Disord 22:1510–1514

    Article  PubMed  Google Scholar 

  • Pacchetti C, Manni R, Zangaglia R et al (2005) Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov Disord 20:1439–1448

    Article  PubMed  Google Scholar 

  • Pappert EJ, Goetz CG, Niederman FG et al (1999) Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov Disord 14:117–121

    Article  CAS  PubMed  Google Scholar 

  • Postuma RB, Gagnon JF, Montplaisir J (2008) Autonomic dysfunction in RBD—what can it teach us about disease progression? Sleep Med 9:473–474

    Article  PubMed  Google Scholar 

  • Rascol O, Dubois B, Caldas AC et al (2006) Early piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN study. Mov Disord 21:2110–2115

    Article  PubMed  Google Scholar 

  • Sanchez-Ramos JR, Ortoll R, Paulson GW (1996) Visual hallucinations associated with Parkinson disease. Arch Neurol 53:1265–1268

    CAS  PubMed  Google Scholar 

  • Schwab R, England A (1969) Projection techniques for evaluating surgery in Parkinson’s disease. In: Edinburgh RCoSi (ed) Third symposium on Parkinson’s disease. E. & S. Livingstone Ltd, pp 152–157

  • Schwab RS, England AC Jr, Poskanzer DC et al (1969) Amantadine in the treatment of Parkinson’s disease. JAMA 208:1168–1170

    Article  CAS  PubMed  Google Scholar 

  • Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson’s disease. Brain 132:2947–2957

    Article  CAS  PubMed  Google Scholar 

  • Shannon KM, Bennett JP Jr, Friedman JH (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology 49:724–728

    CAS  PubMed  Google Scholar 

  • Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG et al (2009) Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 73:1469–1477

    Article  CAS  PubMed  Google Scholar 

  • Williams-Gray CH, Foltynie T, Brayne CE et al (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 13:1787–1798

    Article  Google Scholar 

Download references

Acknowledgments

We thank the patients who agreed to participate to this study and Miss Sophie Bonenfant and Mrs Ange Mabialah for their contribution to data collection and data management. The DoPaMiP survey was funded through the Programme Regional Hospitalier de Recherche Clinique (PHRC 2002–2004) and unrestricted grants from Association France Parkinson from Association pour le Developpement de la Recherche et de l’Enseignment en Neurologie; Boehringer Ingelheim; Eisai; Faust Pharmaceuticals; Euthérapie; GlaxoSmithKline; LN-Pharma start-up; Pierre Fabre Médicaments; Solvay Pharma; Wyeth Lederlé; UPSA Pain Institute.

Conflict of interest

L. Nègre-Pagès owns a start-up company that has worked with Boehringer Ingelheim, Eisai, Faust Pharmaceuticals, Eutherapie, GlaxoSmithKline, Pierre Fabre Médicaments, and Solvay Pharma. R. Debs, V. Cochen De Cock, A. Senard, M. Aristin and O. Rascol have no conflict of interest to declare for the present manuscript.

Author information

Authors and Affiliations

  1. Department of Neurosciences, University Hospital, Toulouse, France

    Rachel Debs, Valérie Cochen De Cock, Anna Senard & Olivier Rascol

  2. Department of Clinical Pharmacology, University Hospital, Toulouse, France

    Laurence Nègre-Pagès & Olivier Rascol

  3. LN-Pharma, Neurosciences Et Neuro-Epidemiology Research Unit, Toulouse, France

    Laurence Nègre-Pagès & Marina Aristin

  4. INSERM U-825/CIC, University Hospital, Toulouse, France

    Olivier Rascol

  5. Centre Atrophie Multi Systématisée, Pavillon Riser, CHU Purpan, TSA 40031, 31059, Toulouse Cedex 9, France

    Valérie Cochen De Cock

Authors
  1. Rachel Debs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valérie Cochen De Cock
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laurence Nègre-Pagès
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marina Aristin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anna Senard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Olivier Rascol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valérie Cochen De Cock.

Additional information

On behalf of the DoPaMiP Study Group.

Appendix: DoPaMiP investigators list

Appendix: DoPaMiP investigators list

G. Angibaud, F. Attané, F. Azais, C. Azais Vuillemin, J.P. Balagué, M. Barreda, M. Benazet, J.M. Boulesteix, C. Carel, D. Castan, M. Chapelle, M.C. Chopin, C. Colombier, L. Damase, A. Danielli, R. Darmanaden, J. David, W. Delage, J.M. Faucheux, S. Fontayne Aguié, A. Fourrier, C. Guiraud Chaumeil, P. Henry, B. Jardillier, J. Rey Zermati, J.R. Rouane, M.H. Rougié, A.M. Salandini, A. Senard, J. Siboni, X. Soulages, N. Stambouli, M. Bonenfant.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Debs, R., Cochen De Cock, V., Nègre-Pagès, L. et al. Thought disorders among non-demented outpatients with Parkinson’s disease: prevalence and associated factors. J Neural Transm 117, 1183–1188 (2010). https://doi.org/10.1007/s00702-010-0458-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-010-0458-8

Keywords

Search

Navigation